Alzheimer's Disease: Competitive Landscape to 2026
Summary
Alzheimer’s disease (AD) is a progressive neurodegenerative disease that is characterized by memory loss, cognitive impairment, and functional decline. The degeneration of neurons starts in the brainstem before progressing to the hippocampus, frontal lobe, amygdala, parietal lobe, and temporal lobe. The cause of AD is unknown, but it appears to be multifactorial, with most research aimed at the Aß peptides and tau proteins. The irregular clearance and metabolism of these proteins are likely contributors to the presentation of the disease. The risk of developing AD is believed to be determined by a combination of genetic, metabolic, behavioral, and environmental factors.
This report provides an assessment of the pipeline, clinical, and commercial landscape of AD. Overall, the author expects new drug approvals to drive AD market growth over the next decade (2016-2026).
Scope
This report combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the slide deck include:
Reasons to buy
Summary
Alzheimer’s disease (AD) is a progressive neurodegenerative disease that is characterized by memory loss, cognitive impairment, and functional decline. The degeneration of neurons starts in the brainstem before progressing to the hippocampus, frontal lobe, amygdala, parietal lobe, and temporal lobe. The cause of AD is unknown, but it appears to be multifactorial, with most research aimed at the Aß peptides and tau proteins. The irregular clearance and metabolism of these proteins are likely contributors to the presentation of the disease. The risk of developing AD is believed to be determined by a combination of genetic, metabolic, behavioral, and environmental factors.
This report provides an assessment of the pipeline, clinical, and commercial landscape of AD. Overall, the author expects new drug approvals to drive AD market growth over the next decade (2016-2026).
Scope
This report combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the slide deck include:
- Pipeline Assessment: regional breakdown, promising late-stage products, early-stage pipeline by molecule type
- Clinical Trials Assessment: trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics
- Commercial Assessment: leading marketed products, current and future players
- Competitive Landscape Analysis: key market events (2016-2026).
Reasons to buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global AD market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AD market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. Pipeline Assessment
5. Clinical Trial Assessment
6 Commercial Assessment
7. Competitive Landscape Analysis (2016-2026)
8 Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Biogen
- Eisai Co.
- F. Hoffmann-La Roche
- Otsuka Pharmaceuticals
- Eli Lilly
- Ionis Pharmaceuticals
- TauRx Therapeutics
- Axsome Therapeutics
- Accera
- Novartis
- AZTherapies
- AB Science
- Grifols
- Shanghai Green Valley Pharmaceutical
- Archer Pharmaceuticals
- Changchun Huayang High-Tech
- Intra-Cellular Therapies
- Avanir Pharmaceuticals
- Promis Neurosciences
- Pfizer
- Johnson & Johnson
- AstraZeneca
- Janssen
- Allergan
- Adamas Pharmaceuticals
- Lundbeck
- Merz Pharma GmbH
- Icure Pharmaceutical
- Shire
- Chase Pharmaceuticals